MedTrace Logo

Minocycline to Prevent Acute Kidney Injury After Cardiac Surgery

NCT00556491 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2017-12-22

Study results available
· View outcomes & findings →

Summary

This study proposes to investigate whether treatment with minocycline pre-operatively in patients with mild to moderate chronic kidney disease undergoing cardiac surgery will reduce the occurence of kidney injury.

Conditions

  • Kidney Failure, Acute
  • Acute Kidney Insufficiency

Interventions

DRUG

minocycline

given at least for 4 doses (200mg initially then 100mg every 12 hours until surgery)with maximum of 14 doses

DRUG

placebo

placebo will be given for at least 4 doses pre-op to a maximum of 14 doses

Sponsors & Collaborators

  • Satellite Healthcare

    collaborator OTHER

  • Triax Pharmaceuticals

    collaborator UNKNOWN

  • Tarek M. El-Achkar

    lead OTHER

Principal Investigators

  • Tarek M El-Achkar, MD · St. Louis University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-12-31
Primary Completion
2011-07-31
Completion
2013-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00556491 on ClinicalTrials.gov